Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 earnings call: what management said on revenue, margins and capex.
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Fredun Pharmaceuticals Ltd Q1 FY26 key numbers
- Revenue
- Ambition to double revenue and PAT within 3 to 4 years, aiming for INR 800+ crore top line and INR 90+ crore PAT.
As stated in Fredun Pharmaceuticals Ltd's Q1 FY26 earnings call transcript · published 28 May 2026. Reported figures, not investment advice.
The short version
Targeting 15% to 20% year-on-year revenue growth overall. Targeting 15% to 20% year-on-year revenue growth going forward.
From Fredun Pharmaceuticals Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Targeting 15% to 20% year-on-year revenue growth overall.
- Ambition to double revenue and PAT within 3 to 4 years, aiming for INR 800+ crore top line and INR 90+ crore PAT.
- Vintage business expected to grow around 15% to 18% annually, supported by 1,290 product registrations in the pipeline.
- New age business, including Fredun Gx and pet care, targeted to reach INR 150 crore in next years with higher gross margins (above 50%).
- Plan to eliminate low-margin products and improve cost efficiencies with expanded manufacturing capacity.
- Anticipate growth from new age segments such as pet care, nutrition, and wellness.
2 more points from Fredun Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Fredun Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Diagnostic center expansion: Planning to open a new diagnostic center in north Mumbai by end of the year; aiming to expand to multiple large cities over next 18 months.
- Per center capex for diagnostic centers estimated around INR 6-8 crores.
- Expansion of manufacturing capacity: Targeting to have one of the largest single-location plants in India within next 18-24 months to support new age business growth.
- Continuous investment in creating efficiencies and manufacturing capabilities to support growth and margin expansion.
2 more points from Fredun Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Fredun Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Fredun Pharmaceuticals has a firm order book valued at around INR 200 crores.
- These orders cover both export and local markets.
- Orders from export markets are confirmed for a 6-month period.
- Local market orders, including third-party orders, also generally cover a 6-month period.
2 more points from Fredun Pharmaceuticals Ltd's call on order book
Create a free account to keep reading this call
Fredun Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹213 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Fredun Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- RPG LifeScience. (Q1 FY26)
168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharma. (Q1 FY26)
Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…
- Morepen Laboratories Ltd (Q1 FY26)
Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- NGL Fine Chem Ltd (Q1 FY26)
Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Fredun Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Fredun Pharmaceuticals Ltd Q1 FY26 results?
Targeting 15% to 20% year-on-year revenue growth overall. Targeting 15% to 20% year-on-year revenue growth going forward.
What is Fredun Pharmaceuticals Ltd share price analysis?
Fredun Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 57.6 with a market cap of ₹2,560 Cr. Investors should review the full earnings analysis for detailed insights.
Is Fredun Pharmaceuticals Ltd planning capital expenditure?
Diagnostic center expansion: Planning to open a new diagnostic center in north Mumbai by end of the year; aiming to expand to multiple large cities over next 18 months.
Keep Fredun Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.